pelvic/lower abdomen right side cramping.; Extremely hyper; could not sleep; horrible muscle pain injection site; swollen lymph node under left arm; said incorrect words when speaking and did not realize it; nose stuffiness; horrible headache; body chills; but face on fire; weak; loss of appetite; extremely tired; fever of 101.4; teeth cold & hurting like nerves exposed; unable to function; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 57 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 09Aug2021 14:30 (Lot number: FC31°01) at the age of 57 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: LISINOPRIL; MONTELUKAST; DOXEPIN. The following information was reported: MUSCLE SPASMS (non-serious) with onset 09Aug2021, outcome "unknown", described as "pelvic/lower abdomen right side cramping."; AGITATION (non-serious) with onset 09Aug2021, outcome "unknown", described as "Extremely hyper"; INSOMNIA (non-serious) with onset 09Aug2021, outcome "unknown", described as "could not sleep"; INJECTION SITE PAIN (non-serious) with onset 09Aug2021, outcome "unknown", described as "horrible muscle pain injection site"; LYMPHADENOPATHY (non-serious) with onset 09Aug2021, outcome "unknown", described as "swollen lymph node under left arm"; LANGUAGE DISORDER (non-serious) with onset 09Aug2021, outcome "unknown", described as "said incorrect words when speaking and did not realize it"; NASAL CONGESTION (non-serious) with onset 09Aug2021, outcome "unknown", described as "nose stuffiness"; HEADACHE (non-serious) with onset 09Aug2021, outcome "unknown", described as "horrible headache"; CHILLS (non-serious) with onset 09Aug2021, outcome "unknown", described as "body chills"; BURNING SENSATION (non-serious) with onset 09Aug2021, outcome "unknown", described as "but face on fire"; ASTHENIA (non-serious) with onset 09Aug2021, outcome "unknown", described as "weak"; DECREASED APPETITE (non-serious) with onset 09Aug2021, outcome "unknown", described as "loss of appetite"; FATIGUE (non-serious) with onset 09Aug2021, outcome "unknown", described as "extremely tired"; PYREXIA (non-serious) with onset 09Aug2021, outcome "unknown", described as "fever of 101.4"; TEETHING (non-serious) with onset 09Aug2021, outcome "unknown", described as "teeth cold & hurting like nerves exposed"; LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (non-serious) with onset 09Aug2021, outcome "unknown", described as "unable to function". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of muscle spasms, agitation, insomnia, injection site pain, lymphadenopathy, language disorder, nasal congestion, headache, chills, burning sensation, asthenia, decreased appetite, fatigue, pyrexia, teething, loss of personal independence in daily activities.  Additional information: The patient did not receive any other vaccine within 4 weeks prior to the COVID vaccine. The patient was not tested for COVID-19 since the vaccination.  Follow-up attempts are completed. No further information is expected.